Basilic vein transposition (BVT) fulfills the need for a durable conduit with high patency and maturation rates. This retrospective review examines a single group's experience with this procedure.

In addition, it includes measures intended to curb “product hopping”, when a manufacturer winds down production of an old drug and forces patients to switch to a newer, in-patent version.

Now two years down the line and Mersana is cutting another 55% of its workforce as it refocuses around its lead breast cancer program. Story May 5 - Bristol Myers Squibb: Big Pharma BMS is on a ...